Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
18 Years
N/A
Both
Liver Neoplasms
Trial Information
Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
An estimated 75 patients (age 18 years of age or older) will be enrolled from the population
of patients who present for ultrasound-guided radiofrequency ablation (RFA) of CT or
MRI-confirmed multiple primary hepatocellular carcinoma (HCC) or metastatic carcinoma, with
at least one of the tumors being ≤ 1.5 cm in diameter.
Inclusion Criteria:
- Patients with primary hepatocellular carcinoma (HCC) or secondary (metastatic)
carcinoma of the liver who have been referred for ultrasound-guided radiofrequency
ablation (RFA) treatment
- Recent (within 90 days) CT or MRI scan with report of one or more tumors ≤ 1.5 cm in
diameter
- Patient is stable and is to be managed conservatively (i.e. non-surgically)
- 18 years of age or older
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Known or suspected cardiac shunt(s)
- Known sensitivity to octafluoropropane
- Pregnant or breastfeeding
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
estimation of the the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
John P. McGahan, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
UC Davis School of Medicine Dept. of Radiology
Authority:
United States: Institutional Review Board
Study ID:
200715241
NCT ID:
NCT00584402
Start Date:
April 2007
Completion Date:
March 2009
Related Keywords:
- Liver Neoplasms
- liver cancer
- Neoplasms
- Liver Neoplasms
Name | Location |
|---|---|
| UC Davis Medical Center | Sacramento, California 95817 |
